Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02289950
Title A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Morphotek
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

Therapies

Farletuzumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.